Literature DB >> 29682811

Upregulation of hypothalamic arginine vasopressin by peripherally administered furosemide in transgenic rats expressing arginine vasopressin-enhanced green fluorescent protein.

Hiromichi Ueno1,2, Mitsuhiro Yoshimura1, Kentaro Tanaka1, Haruki Nishimura1, Kazuaki Nishimura1, Satomi Sonoda1, Yasuhito Motojima1, Reiko Saito1, Takashi Maruyama1, Tetsu Miyamoto2, Ryota Serino3, Masahito Tamura2, Tatsushi Onaka4, Yutaka Otsuji2, Yoichi Ueta1.   

Abstract

Furosemide, which is used worldwide as a diuretic agent, inhibits sodium reabsorption in the Henle's loop, resulting in diuresis and natriuresis. Arginine vasopressin (AVP) is synthesized in the supraoptic nucleus (SON), paraventricular nucleus (PVN), and suprachiasmatic nucleus (SCN) of the hypothalamus. The synthesis AVP in the magnocellular neurons of SON and PVN physiologically regulated by plasma osmolality and blood volume and contributed water homeostasis by increasing water reabsorption in the collecting duct. Central AVP dynamics after peripheral administration of furosemide remain unclear. Here, we studied the effects of intraperitoneal (i.p.) administration of furosemide (20 mg/kg) on hypothalamic AVP by using transgenic rats expressing AVP-enhanced green fluorescent protein (eGFP) under the AVP promoter. The i.p. administration of furosemide did not affect plasma osmolality in the present study; however, eGFP in the SON and magnocellular divisions of the PVN (mPVN) were significantly increased after furosemide administration compared to the control. Immunohistochemical analysis revealed Fos-like immunoreactivity (IR) in eGFP-positive neurons in the SON and mPVN 90 min after i.p. administration of furosemide, and AVP heteronuclear (hn) RNA and eGFP mRNA levels were significantly increased. These furosemide-induced changes were not observed in the suprachiasmatic AVP neurons. Furthermore, furosemide induced a remarkable increase in Fos-IR in the organum vasculosum laminae terminals (OVLT), median preoptic nucleus (MnPO), subfornical organ (SFO), locus coeruleus (LC), nucleus of the solitary tract (NTS), and rostral ventrolateral medulla (RVLM) after i.p. administration of furosemide. In conclusion, we were able to visualize and quantitatively evaluate AVP-eGFP synthesis and neuronal activations after peripheral administration of furosemide, using the AVP-eGFP transgenic rats. The results of this study may provide new insights into the elucidation of physiological mechanisms underlying body fluid homeostasis induced by furosemide. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.

Entities:  

Keywords:  Furosemide; Hypothalamus; In situ hybridization; Transgenic rat; Vasopressin; Water balance

Year:  2018        PMID: 29682811     DOI: 10.1111/jne.12603

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  3 in total

1.  Effects of acute kidney dysfunction on hypothalamic arginine vasopressin synthesis in transgenic rats.

Authors:  Hiromichi Ueno; Ryota Serino; Kenya Sanada; Yasuki Akiyama; Kentaro Tanaka; Haruki Nishimura; Kazuaki Nishimura; Satomi Sonoda; Yasuhito Motojima; Reiko Saito; Mitsuhiro Yoshimura; Takashi Maruyama; Tetsu Miyamoto; Masahito Tamura; Yutaka Otsuji; Yoichi Ueta
Journal:  J Physiol Sci       Date:  2019-04-01       Impact factor: 2.781

Review 2.  Sensory Circumventricular Organs, Neuroendocrine Control, and Metabolic Regulation.

Authors:  Jin Kwon Jeong; Samantha A Dow; Colin N Young
Journal:  Metabolites       Date:  2021-07-29

3.  Oxytocin-monomeric red fluorescent protein 1 synthesis in the hypothalamus under osmotic challenge and acute hypovolemia in a transgenic rat line.

Authors:  Hiromichi Ueno; Kenya Sanada; Tetsu Miyamoto; Kazuhiko Baba; Kentaro Tanaka; Haruki Nishimura; Kazuaki Nishimura; Satomi Sonoda; Mitsuhiro Yoshimura; Takashi Maruyama; Yasushi Oginosawa; Masaru Araki; Shinjo Sonoda; Tatsushi Onaka; Yutaka Otsuji; Yoichi Ueta
Journal:  Physiol Rep       Date:  2020-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.